Bayer Consolidates Next-Generation Gene Editing Focus With Mammoth Deal
Pays $40m
The German major will collaborate with the US biotech to develop CRISPR gene-editing therapies, solidifying its interest in next-generation therapeutics.
The German major will collaborate with the US biotech to develop CRISPR gene-editing therapies, solidifying its interest in next-generation therapeutics.